Novo Nordisk receives EU marketing authorisation for insulin analogues  

2005.10.12
The European Medicines Agency has granted EU marketing authorisation to Denmark's Novo Nordisk for its new premix insulin analogues NovoMix 50 and NovoMix 70 for the treatment of diabetes

The European Medicines Agency has granted EU marketing authorisation to Denmark's Novo Nordisk for its new premix insulin analogues NovoMix 50 and NovoMix 70 for the treatment of diabetes. The authorisation has been granted faster than expected. The products complement Novo Nordisk's portfolio of premixed insulins which contain both rapid and intermediate acting insulin. The number in the NovoMix product name indicates the percentage of rapid-acting insulin in the mixture.

Mads Krogsgaard Thomsen, chief science officer at Novo Nordisk comments: "These products will give people with diabetes and healthcare professionals additional options when there is a need for greater post-prandial glucose control, but a desire to stay on a simple and yet effective therapy". The news was reported by financial daily newspaper Børsen and on the Novo Nordisk website.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 21,200 people in 78 countries.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×